The JAK2 inhibitor fedratinib has been reported to reduce mortality from COVID-19 [119] and ruxolitinib (a tyrosine kinase inhibitor) inhibits viral infection by inhibition of JAK1 and JAK2 and other JAK inhibitors can block cytokine release associated with COVID-19-induced cytokine storm [120]. Here, JAK1 is linked to COVID-19.